McKesson Stock-Based Compensation 2010-2025 | MCK
McKesson annual/quarterly stock-based compensation history and growth rate from 2010 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
- McKesson stock-based compensation for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
- McKesson stock-based compensation for the twelve months ending March 31, 2025 was $0M, a 0% increase year-over-year.
- McKesson annual stock-based compensation for 2025 was $0B, a 0% decline from 2024.
- McKesson annual stock-based compensation for 2024 was $0B, a 0% decline from 2023.
- McKesson annual stock-based compensation for 2023 was $0B, a 0% decline from 2022.
McKesson Annual Stock-Based Compensation
(Millions of US $) |
| 2025 |
$N/A |
| 2024 |
$N/A |
| 2023 |
$N/A |
| 2022 |
$N/A |
| 2021 |
$N/A |
| 2020 |
$N/A |
| 2019 |
$N/A |
| 2018 |
$N/A |
| 2017 |
$N/A |
| 2016 |
$123 |
| 2015 |
$174 |
| 2014 |
$160 |
| 2013 |
$167 |
| 2012 |
$154 |
| 2011 |
$137 |
| 2010 |
$114 |
| 2009 |
$99 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$85.362B |
$359.051B |
|
McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
|
